CalciMedica (CALC) Cash from Financing Activities (2019 - 2026)
CalciMedica's (CALC) quarterly Cash from Financing Activities came in at $3.8 million in Q4 2025, down 57.92% YoY from $8.9 million in Q4 2024, and up 358.92% on a QoQ basis from $818000.0 in Q3 2025.
CalciMedica (CALC) Cash from Financing Activities (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 7 years of Cash from Financing Activities data on file, last reported at $3.8 million in Q4 2025.
- Quarterly Cash from Financing Activities fell 57.92% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 77.28% YoY) and the FY2025 annual result came in at $15.2 million, down 45.62% from the prior year.
- Cash from Financing Activities advanced to $3.8 million in Q4 2025, from $818000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $23.5 million in Q1 2023 to a low of -$2.9 million in Q2 2023.
- A 5-year average of $3.7 million and a median of $335000.0 in 2021 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 2351400.0% — and 2025, when it sank 1357.14%.
- Tracing CALC's Cash from Financing Activities over 5 years: stood at $81000.0 in 2021, then soared by 6651.85% to $5.5 million in 2022, then slumped by 96.8% to $175000.0 in 2023, then soared by 4998.29% to $8.9 million in 2024, then tumbled by 57.92% to $3.8 million in 2025.
- The last three Cash from Financing Activities figures came in at $3.8 million (Q4 2025), $818000.0 (Q3 2025), and -$102000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | 15.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.03 Mn |
| Jun 30, 2026 | 15.03 Mn |
| Dec 31, 2025 | 3.75 Mn |
| Dec 31, 2025 | 3.75 Mn |
| Sep 30, 2025 | 818,000.00 |
| Sep 30, 2025 | 818,000.00 |
| Jun 30, 2025 | -102,000.00 |
| Jun 30, 2025 | -102,000.00 |
| Mar 31, 2025 | 10.74 Mn |
| Mar 31, 2025 | 10.74 Mn |
| Dec 31, 2024 | 8.92 Mn |
| Dec 31, 2024 | 8.92 Mn |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | 19.04 Mn |
| Mar 31, 2024 | 19.04 Mn |
| Dec 31, 2023 | 175,000.00 |
| Dec 31, 2023 | 175,000.00 |